• Publications
  • Influence
Partial left ventriculectomy to treat end-stage heart disease.
BACKGROUND It is reasoned that reducing left ventricular diameter (Laplace's law) in patients with dilated cardiomyopathy, will improve ventricular function. METHODS Partial left ventriculectomyExpand
  • 370
  • 16
The Use of 18F-FDG PET in the Diagnosis of Cardiac Sarcoidosis: A Systematic Review and Metaanalysis Including the Ontario Experience
Cardiac sarcoidosis is a potentially fatal complication of sarcoidosis. The 1993 guidelines of the Ministry of Health, Labour, and Welfare (MHLW) of Japan have been used as the diagnostic goldExpand
  • 348
  • 13
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
BACKGROUND Recurrent ventricular tachycardia among survivors of myocardial infarction with an implantable cardioverter-defibrillator (ICD) is frequent despite antiarrhythmic drug therapy. The mostExpand
  • 331
  • 11
Device‐Related Infection Among Patients With Pacemakers and Implantable Defibrillators: Incidence, Risk Factors, and Consequences
Risk Factors and Complications of Pacemaker and ICD Infection. Background: Device‐related infection is a major limitation of device therapy for cardiac arrhythmia.
  • 177
  • 5
Cardiac manifestations of sarcoidosis: diagnosis and management
Approximately 5% of patients with sarcoidosis will have clinically manifest cardiac involvement presenting with one or more of ventricular arrhythmias, conduction abnormalities, and heart failure.Expand
  • 47
  • 5
Clinical Predictors of Fidelis Lead Failure: Report From the Canadian Heart Rhythm Society Device Committee
Background— Approximately 268 000 Fidelis leads were implanted worldwide until distribution was suspended because of a high rate of early failure. Careful analyses of predictors of increased leadExpand
  • 110
  • 4
  • PDF
Atrioesophageal fistula in the era of atrial fibrillation ablation: a review.
The purpose of this review is to understand the epidemiology, clinical features, etiopathogenesis, and management of atrioesophageal fistula (AEF) after atrial fibrillation (AF) ablation. TheExpand
  • 66
  • 4
Greater response to cardiac resynchronization therapy in patients with true complete left bundle branch block: a PREDICT substudy.
AIMS Cardiac resynchronization therapy (CRT) benefits patients with heart failure and a wide QRS complex. Still, one-third derive no clinical benefit and a majority of patients demonstrate noExpand
  • 23
  • 4
Cardiac Sarcoidosis.
Clinically manifest cardiac involvement occurs in perhaps 5% of patients with sarcoidosis. The 3 principal manifestations of cardiac sarcoidosis (CS) are conduction abnormalities, ventricularExpand
  • 27
  • 4
  • PDF
Corticosteroid therapy for cardiac sarcoidosis: a systematic review.
BACKGROUND There are no published clinical consensus guidelines or systematic evaluation supporting the use of corticosteroids for the treatment of cardiac sarcoidosis. The purpose of this study wasExpand
  • 126
  • 3
...
1
2
3
4
5
...